Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer

被引:0
|
作者
Xu, T [1 ]
Wang, XF [1 ]
Hou, SK [1 ]
Zhu, JC [1 ]
Zhang, XD [1 ]
Huang, XB [1 ]
机构
[1] Peking Univ, People Hosp, Dept Urol, Beijing 100044, Peoples R China
关键词
prostate cancer; androgens; arteriosclerosis;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To analyze the effect of castration on risk factors for arteriosclerosis of patients with prostate cancer. Methods Thirty patients with primary regional prostate adenocarcinoma limited to the prostate theca were selected in this study. Serum levels of testosterone (T), free testosterone ( FT), dehydroepiandrosterone (DHEA), sex hormone-binding globulin (SHBG), prostatic specific antigen (PSA), triglyceride (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apoprotein alpha(1) (APOalpha(1)) and apoprotein beta (APObeta), insulin, plasma fibrinopeptide A ( FPA), plasminogen activator inhibitor-1 (PAI-1) and fibrinogen were determined just prior to, 1 week and 1, 4 and 8 months after castration. Results T, FT and PSA decreased significantly 1 week after castration (21.12 +/- 15.11 ng/ml vs 383.9 +/- 62.6 ng/ml, P < 0.001; 4.08 +/- 3.29 pmol/L vs 34.11 +/- 11.59 pmol/L, P < 0.001; 14.34 +/- 7.77 ng/ml vs 23.51 +/- 6.57 ng/ml, P = 0.001, respectively) and continued to decrease until reaching their lowest levels 8 months after castration. DHEA and SHBG did not undergo any changes. TG, fasting insulin and glucose, 2-hour insulin and glucose levels were significantly elevated 1 month after castration (1.84 +/- 0.61 mmol/L vs 1.30 +/- 0.40 mmol/L, P < 0.05; 18.16 +/- 5.57 mU/L vs 9.47 +/- 3.81 mU/L, P < 0.05; 4.77 +/- 0.66 mmol/L vs 3.92 +/- 0.34 mmol/L, P < 0. 05; 65.52 +/- 14.78 mU/L vs 36.94 +/- 17.12 mU/L, P < 0.01; 6.98 +/- 0.79 mmol/L vs 6.01 +/- 0.23 mmol/L, P = 0.001, respectively). TC, LDL-C, FPA and PAI-1 levels were elevated 4 months after castration (6.56 +/- 0.99 mmol/L vs; 5.29 +/- 0.75 mmol/L, P < 0.01; 4.09 +/- 0.86 mmol/L vs 3.04 +/- 0.15 mmol/L, P < 0.01; 3.39 +/- 1.67 nmol/L vs 1.48 +/- 0.50 nmol/L, P < 0. 01; 27.02 +/- 5.98 ng/ml vs 21.78 +/- 3.16 ng/ml, P < 0. 05, respectively), continuing to increase after that point. Insulin sensitive index (ISI) decreased significantly 1 month after surgery (-4.42 +/- 0.36 vs - 3.50 +/- 0.39, P < 0.001), and continued to decrease from that point forward. HDL-C, APOal, APOP and fibrinogen remained at pre-operative levels. There was a negative linear correlation between FT and TG, TC, LDL-C, PAI-1, FPA, fasting insulin and glucose, 2-hour insulin and glucose ( r = - 0. 311, - 0.384, - 0.385, - 0.339, - 0.353, - 0.381, - 0.303, - 0.460 and - 0. 395, respectively; P < 0.05). A similar phenomenon occurred with T ( r = - 0.308, - 0.309, - 0.356, - 0. 320, - 0.430, - 0.453, - 0.435, - 0.483 and - 0. 512, respectively; P &LT; 0.05). T and FT were positively associated with ISI ( r = 0. 555 and 0. 501; P &LT; 0.001). Conclusions At 8 months follow-up of the study subjects, we found that lower androgen levels have adverse effects on lipid metabolism, coagulative function and insulin sensitivity, related to arteriosclerosis in men.
引用
收藏
页码:1336 / 1340
页数:5
相关论文
共 50 条
  • [1] Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
    Lin, Ting-Ting
    Chen, Ye-Hui
    Wu, Yu-Peng
    Chen, Shao-Zhan
    Li, Xiao-Dong
    Lin, Yun-Zhi
    Chen, Shao-Hao
    Zheng, Qing-Shui
    Wei, Yong
    Xu, Ning
    Xue, Xue-Yi
    JOURNAL OF CANCER, 2019, 10 (22): : 5608 - 5613
  • [2] Surgical versus medical castration in prostate cancer patients
    Nature Clinical Practice Urology, 2005, 2 (1): : 4 - 4
  • [3] Surgical versus medical castration in prostate cancer patients
    Nature Clinical Practice Oncology, 2005, 2 (1): : 9 - 10
  • [4] Surgical castration and prostate cancer
    Rebillard, X
    Ruffion, A
    PROGRES EN UROLOGIE, 2005, 15 (05): : 1147 - 1148
  • [5] Risk and prognostic factors of castration resistant prostate cancer
    Zhang, Kaiyan
    Xing, Jinchun
    Li, Wei
    Wu, Zhun
    Wang, Xuegang
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 455 - 455
  • [6] EFFECT OF PROSTATE CANCER TREATMENT TYPES ON CARDIOVASCULAR DISEASE RISK FACTORS IN PROSTATE CANCER PATIENTS
    Bassey, Iya Eze
    Udoh, Alphonsus E.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 165 - 165
  • [7] Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer
    Masaki Shiota
    Akira Yokomizo
    Ario Takeuchi
    Keijiro Kiyoshima
    Junichi Inokuchi
    Katsunori Tatsugami
    Seiji Naito
    Supportive Care in Cancer, 2014, 22 : 3219 - 3226
  • [8] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
    Procopio, Giuseppe
    Grassi, Paolo
    Testa, Isabella
    Verzoni, Elena
    Torri, Valter
    Salvioni, Roberto
    Valdagni, Riccardo
    de Braud, Filippo
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05): : 479 - 482
  • [9] Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer
    Shiota, Masaki
    Yokomizo, Akira
    Takeuchi, Ario
    Kiyoshima, Keijiro
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Naito, Seiji
    SUPPORTIVE CARE IN CANCER, 2014, 22 (12) : 3219 - 3226
  • [10] Analysis of risk factors leading to anxiety and depression in patients with prostate cancer after castration and the construction of a risk prediction model
    Li, Rui-Xiao
    Li, Xue-Lian
    Wu, Guo-Jun
    Lei, Yong-Hua
    Li, Xiao-Shun
    Li, Bo
    Ni, Jian-Xin
    WORLD JOURNAL OF PSYCHIATRY, 2024, 14 (02):